[go: up one dir, main page]

AP2001002153A0 - Methods and compositions for restoring conformational stability of a protein of the p53 family. - Google Patents

Methods and compositions for restoring conformational stability of a protein of the p53 family.

Info

Publication number
AP2001002153A0
AP2001002153A0 APAP/P/2001/002153A AP2001002153A AP2001002153A0 AP 2001002153 A0 AP2001002153 A0 AP 2001002153A0 AP 2001002153 A AP2001002153 A AP 2001002153A AP 2001002153 A0 AP2001002153 A0 AP 2001002153A0
Authority
AP
ARIPO
Prior art keywords
protein
methods
family
compositions
restoring
Prior art date
Application number
APAP/P/2001/002153A
Inventor
Heater Anne Coffey
Richard Damian Connell
Barbara Ann Foster
Farzan Rastinejad
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2001002153A0 publication Critical patent/AP2001002153A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention is in the field of cancer treatment. In particular, the present invention provides pharmaceutical compounds capable of interacting with mutant and non-mutant forms of cancer-related regulatory proteins such that the mutant protein regains the capacity to properly interact with other macromolecules, thereby restoring or stabilizing all or a portion of its wild type activity. Regulatory proteins include members of the p53 protein family such as for example, p53, p63 and p73. The compounds of the invention are useful for cancer treatment. Methods for screening for such pharmacological compounds are also provided.
APAP/P/2001/002153A 1998-12-02 1999-12-01 Methods and compositions for restoring conformational stability of a protein of the p53 family. AP2001002153A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11054298P 1998-12-02 1998-12-02
PCT/IB1999/001916 WO2000032175A2 (en) 1998-12-02 1999-12-01 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY

Publications (1)

Publication Number Publication Date
AP2001002153A0 true AP2001002153A0 (en) 2001-06-30

Family

ID=22333594

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002153A AP2001002153A0 (en) 1998-12-02 1999-12-01 Methods and compositions for restoring conformational stability of a protein of the p53 family.

Country Status (25)

Country Link
US (1) US20020048271A1 (en)
EP (1) EP1137418A2 (en)
JP (2) JP2002531396A (en)
KR (1) KR20010086073A (en)
CN (1) CN1329493A (en)
AP (1) AP2001002153A0 (en)
AU (1) AU1290700A (en)
BG (1) BG105599A (en)
BR (1) BR9915940A (en)
CA (1) CA2350597A1 (en)
EA (1) EA003326B1 (en)
EE (1) EE200100302A (en)
HK (1) HK1041644A1 (en)
HR (1) HRP20010414A2 (en)
HU (1) HUP0201215A2 (en)
ID (1) ID29061A (en)
IL (1) IL143094A0 (en)
IS (1) IS5943A (en)
NO (1) NO20012737L (en)
OA (1) OA11722A (en)
PL (1) PL348310A1 (en)
TR (1) TR200101549T2 (en)
WO (1) WO2000032175A2 (en)
YU (1) YU35401A (en)
ZA (1) ZA200104210B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2002310497A1 (en) * 2001-06-20 2003-01-08 Caprion Pharmaceuticals Inc. Protein aggregation assays and uses thereof
CA2454768A1 (en) * 2001-08-10 2003-02-20 Medical Research Council Molecule
WO2004034013A2 (en) * 2002-05-06 2004-04-22 Colorado State University Research Foundation Genotoxicity analysis
WO2004030671A2 (en) * 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
ES2272911T3 (en) * 2003-04-25 2007-05-01 Neurofit Sas USE OF PIPERAZINE PHENOTIAZINE DERIVATIVES IN THE MANUFACTURE OF A MEDICINAL PRODUCT WITH NEUROPROTECTOR AND / OR NEUROTROPHIC EFFECTS ON CNS AND / OR PNS.
US6970791B1 (en) * 2003-05-23 2005-11-29 Verachem, Llc Tailored user interfaces for molecular modeling
US7618975B2 (en) * 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
JP2007512341A (en) * 2003-11-21 2007-05-17 メルク　エンド　カムパニー　インコーポレーテッド Pyridin-4-ylamine compounds useful for the treatment of neuropathic pain
JPWO2005061007A1 (en) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 Cancer control method
CN1909927A (en) * 2003-12-24 2007-02-07 株式会社洛科摩基因 Method of suppressing cancer
EP1781293A1 (en) * 2004-06-04 2007-05-09 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7790474B1 (en) 2005-07-15 2010-09-07 Schering Corporation p53 modulators
CA2615373A1 (en) * 2005-07-15 2007-01-25 Schering Corporation Quinazoline derivatives useful in cancer treatment
WO2007107543A1 (en) 2006-03-22 2007-09-27 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
CA2644649C (en) 2006-03-22 2014-06-17 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
NZ546477A (en) * 2006-04-07 2009-04-30 Auckland Uniservices Ltd 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
MX2009000418A (en) 2006-07-10 2009-08-12 Univ Columbia Anti-cocaine compositions and treatment.
WO2008155441A1 (en) 2007-06-20 2008-12-24 Marikki Laiho Activators and therapeutic applications thereof
BRPI0813556A2 (en) 2007-07-10 2015-06-16 Univ Columbia Protein thermostabilization
WO2009019274A1 (en) 2007-08-06 2009-02-12 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between mdm2 and p53
TWI476189B (en) 2009-02-04 2015-03-11 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
US20130102627A1 (en) * 2010-04-09 2013-04-25 The Brigham And Women's Hospital, Inc. Acridines As Inhibitors Of Haspin And DYRK Kinases
WO2012154879A2 (en) 2011-05-09 2012-11-15 Van Andel Research Institute Autophagy inhibitors
WO2013043744A2 (en) 2011-09-21 2013-03-28 Inception 1, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN102660257B (en) * 2012-05-22 2013-11-27 南京邮电大学 Phenothiazinylquinazoline Fluorescent Ion Probes and Their Applications
PT3201234T (en) 2014-09-30 2019-02-05 Diadem S R L Antibody binding a linear epitope of human p53 and diagnostic applications thereof
CN105399671B (en) * 2015-12-02 2018-04-17 广西中医药大学 7 p-totuidine base benzo [c] acridine hydrochlorides and its preparation method and application
CN105418501B (en) * 2015-12-02 2018-04-17 广西中医药大学 7 pairs of anisidino- benzo [c] acridine hydrochlorides and its preparation method and application
CN105399670B (en) * 2015-12-02 2018-04-17 广西中医药大学 A kind of benzo (c) acridinium carboxamide base thiourea derivative and its preparation method and application
CA3012302A1 (en) * 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
US10138219B2 (en) * 2016-02-19 2018-11-27 Pmv Pharmaceuticals Methods and compounds for restoring mutant p53 function
CN109694358B (en) * 2019-01-23 2022-02-08 广西师范大学 2-p-nitrostyryl-4-substituted aminoquinazoline derivative and preparation method and application thereof
KR102838154B1 (en) * 2019-09-23 2025-07-28 피엠브이 파마슈티컬스 인코포레이티드 Methods and compounds for restoring mutant p53 function
US20210405056A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. Methods for detecting mutant p53 function
KR20230028484A (en) 2020-06-24 2023-02-28 피엠브이 파마슈티컬스 인코포레이티드 Combination therapy for the treatment of cancer
GB202111035D0 (en) * 2021-07-30 2021-09-15 Vestlandets Innovasjonsselskap As Therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
CA2185116A1 (en) * 1994-03-08 1995-09-14 Thomas P. Wallace Recombinant humanized anti-fb5 antibodies
EP0815202B1 (en) * 1994-12-13 2007-02-21 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US5900360A (en) * 1996-04-10 1999-05-04 Welch; William J. Correction of genetic defects using chemical chaperones
US6270954B1 (en) * 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
DE19624154A1 (en) * 1996-06-18 1998-01-08 Hoechst Ag Ring-fused dihydropyrans, process for their preparation and their use
US5932613A (en) * 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
KR20000035920A (en) * 1996-08-28 2000-06-26 데이비드 엠 모이어 Heterocyclic metalloprotease inhibitors
UA56185C2 (en) * 1996-09-30 2003-05-15 Пфайзер Інк. Aralkyl- and aralkylidene heterocyclic lactams and imids, a pharmaceutical composition and a treatment method
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6284923B1 (en) * 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
US6387903B1 (en) * 1997-08-27 2002-05-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
FI105554B (en) * 1998-05-13 2000-09-15 Galilaeus Oy Hybrid anthracyclines from genetically modified streptomyces galilaeus strains
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
EP1104761B1 (en) * 1998-08-12 2004-10-13 Daiichi Pure Chemicals Co., Ltd. Fluorescent labelling reagents
SE9900941D0 (en) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
FR2788696B1 (en) * 1999-01-26 2004-03-05 Synthelabo USE OF PYRIDAZINO [4,5-B] INDOLE-1-ACETAMIDE DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM
WO2000066125A1 (en) * 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
AU7847800A (en) * 1999-10-15 2001-04-30 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
US6372785B1 (en) * 2000-05-04 2002-04-16 Keith Chan, President Globoasia, Llc Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6395771B1 (en) * 2000-05-31 2002-05-28 Dabur Research Foundation Paclitaxel derivatives for the treatment of cancer
US6391916B1 (en) * 2000-07-21 2002-05-21 The Hong Kong University Of Science And Technology Enediyne derivatives

Also Published As

Publication number Publication date
EP1137418A2 (en) 2001-10-04
CA2350597A1 (en) 2000-06-08
KR20010086073A (en) 2001-09-07
WO2000032175A2 (en) 2000-06-08
JP2002531396A (en) 2002-09-24
JP2006166920A (en) 2006-06-29
HRP20010414A2 (en) 2002-06-30
BR9915940A (en) 2001-09-11
NO20012737D0 (en) 2001-06-01
PL348310A1 (en) 2002-05-20
EE200100302A (en) 2002-08-15
EA200100502A1 (en) 2001-12-24
WO2000032175A3 (en) 2000-08-03
IL143094A0 (en) 2002-04-21
TR200101549T2 (en) 2001-11-21
HK1041644A1 (en) 2002-07-19
HUP0201215A2 (en) 2002-08-28
EA003326B1 (en) 2003-04-24
NO20012737L (en) 2001-07-09
ID29061A (en) 2001-07-26
OA11722A (en) 2005-01-25
CN1329493A (en) 2002-01-02
YU35401A (en) 2005-07-19
US20020048271A1 (en) 2002-04-25
AU1290700A (en) 2000-06-19
IS5943A (en) 2001-05-15
BG105599A (en) 2002-02-28
ZA200104210B (en) 2003-02-24

Similar Documents

Publication Publication Date Title
AP2001002153A0 (en) Methods and compositions for restoring conformational stability of a protein of the p53 family.
DK0600866T3 (en) Preparations and Methods for Identifying Biologically Active Molecules
DE69202207D1 (en) Process for the preparation of 1-chloro-1,1,3,3,3-pentafluoropropane and 1,1,1,3,3,3-hexafluoropropane.
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
IL126038A0 (en) Novel benzothiepines and derivatives thereof and pharmaceutical compositions comprising them
EP1374875A3 (en) Pharmaceutical compositons comprising arsenic for the treatment of myelodysplastic syndrome
TR200102817T2 (en) Compounds useful as anti-inflammatory agents
ATE109145T1 (en) HETEROCYCLIC ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
DE60142614D1 (en) INITÄT
DE69738961D1 (en) SCREENING OF COMPOUNDS TO THEIR ABILITY TO MODIFY THE PREPARATION OF BETA-AMYLOID PEPTIDES
DE69915693D1 (en) 2,5-DIAZABICYCLO (2.2.1) HEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN MEDICATION
NO972451L (en) Heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and preparations and process for use thereof
IL146125A0 (en) Novel quinones as disease therapies
DE69804659D1 (en) 21-HYDRO-6,19-OXIDOPROGESTERONE (21OH-60P) AND THE USE THEREOF AS A MEDICINE FOR TREATING GLUCOCORTICO excess
EP0797999A3 (en) Formulations of obesity protein
AU1319895A (en) Cyclodextrin derivatives for solubilising hydrophobic chemical compounds such as drugs, and methods for preparing same
FR2662698B1 (en)
ATE253917T1 (en) PRODUCTS CONTAINING NRIHYDROXISTILBENES AND THEIR DERIVATIVES AND METHODS FOR THE PRODUCTION THEREOF AND THEIR USE
DE69927584D1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF STOMACH DISEASES
ATE213944T1 (en) USE OF IMMUNOMODULATORS
ZA976967B (en) Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the of said device.
DE69510356D1 (en) ANTI-SICKLING BETA-GLOBIN, COMPOSITION AND METHOD FOR THE TREATMENT OF SICKLE LEL ANALIA
DE3750067D1 (en) Disazo compounds and preparations containing these Disazo compounds.
DE69916488D1 (en) SUBSTITUTED CAPROLACTAM DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AND THEIR USE FOR THE TREATMENT OF TUMORS
DK0719276T3 (en) Estradiol esters with strong oral action as well as pharmaceutical preparations containing them